Diagnos, Inc.

Diagnos, Inc. is a healthcare technology company specializing in AI-driven solutions for early detection of critical health issues, such as eye diseases. The company aims to enhance patient outcomes through innovative diagnostic tools. Founded in 1998 in Brossard, Canada, Diagnos, Inc.

focuses on developing artificial intelligence technologies for healthcare applications. The company was involved in a significant merger in May 2014, acquiring Warnex, Inc. , a portfolio company of Persistence Capital Partners, with the deal completed in July 2014. André Larente is the CEO of Diagnos, leading the firm in its operations and strategic direction.

Diagnos specializes in artificial intelligence-driven healthcare solutions, primarily focusing on the early detection of critical health issues, particularly eye diseases such as diabetic retinopathy. Their flagship product, the CARA platform, functions as a robust tool for importing, processing, and storing both original and enhanced medical images through computerized networks. This technology facilitates healthcare professionals in primary care settings to closely monitor the impacts of diabetes and other chronic conditions, addressing a significant need for early intervention to prevent vision loss. Diagnos serves a diverse client base that includes government health departments, healthcare providers, and institutions across various countries, with notable operations in Mexico and North America.

The company's services are designed to enhance patient outcomes and streamline healthcare services, contributing to improved health management in markets that include Latin America, North America, and potentially other regions where chronic diseases are prevalent. In the most recent fiscal year, 2014, Diagnos reported revenue of USD 2. 92 mn and an EBITDA of USD -1. 04 mn.

The company's revenue model is structured around providing advanced AI tools and services to healthcare organizations, which are essential for effective disease screening and monitoring. Clients engage through partnerships and subscriptions to use the CARA platform and other diagnostic services, reflecting the value of their technology in delivering critical health insights. Looking ahead, Diagnos plans to enhance its product offerings with new features and capabilities in the CARA platform, although specific upcoming releases have not been disclosed. The company is targeting expansion into additional markets, including further penetration into Latin America and possibly exploring opportunities in regions where chronic diseases are prevalent.

The financial backing from the acquisition of Warnex, Inc. will support these initiatives, allowing Diagnos to strengthen its technological capabilities and expand its geographic footprint.